GW Pharmaceuticals Plc (NASDAQ:GWPH) dropped by -0.68 or -0.61 points during the last session to $89.08 per share. One of the highlights of the day was the net money flow figure, which stood at $0.82 million even as the stock accepted $2.72 million in upticks but rejected $1.9 million in downticks. The up/down ratio for the last observation was a 1.43. The 1-week percentage change for the stock price is registered at -3.27%.
Institutional Investors own 65.06% of GW Pharmaceuticals Plc shares.
GW Pharmaceuticals Plc (NASDAQ:GWPH) stock ended Monday session in the red zone in a volatile trading. The stock closed down 2.55 points or 2.84% at $87.14 with 397,033 shares getting traded. Post opening the session at $88.95, the shares hit an intraday low of $86.5 and an intraday high of $90.28 and the price was in this range throughout the day. The company has a market cap of $1,897 million and the number of outstanding shares have been calculated to be 21,765,014 shares. The 52-week high of GW Pharmaceuticals Plc (NASDAQ:GWPH) is $133.98 and the 52-week low is $35.83.
Many analysts have stated their opinion on the company shares. Cantor Fitzgerald initiates coverage on GW Pharmaceuticals Plc (NASDAQ:GWPH) . The global brokerage major announces a current price target of $181 per share. Analysts at the Cantor Fitzgerald have a current rating of Buy on the shares. The rating by the firm was issued on June 2, 2016.
GW Pharmaceuticals plc is a United Kingdom-based biopharmaceutical company. The Company is engaged developing a portfolio of cannabinoid medicines, including Sativex for the treatment of multiple sclerosis spasticity and cancer pain, and Epidiolex for the treatment of childhood epilepsy. The Company also engaged in developing cannabinoids, medicines containing controlled substances, as well as plant-based prescription pharmaceutical products. The Companys product, Sativex is approved in 27 countries and is used as a treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS). The Sativex is also in Phase III clinical development for the treatment of cancer pain, the indication for the United States market.